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Background: A range of negative experiences and circumstances that are common among people who 18 
inject drugs (PWID) are risk factors for developing mental disorders. Despite this, there has been no 19 
systematic review of the prevalence of mental health indicators among PWID. Thus, we aimed to 20 
estimate the prevalence of depression, post-traumatic stress disorder (PTSD), suicidality and self-21 
harm among PWID. 22 
Methods: We searched the peer-reviewed and grey literature for data on depression, PTSD, suicidality 23 
and non-suicidal self-harm among PWID from sources published from 2008-2018. We pooled 24 
estimates of depression and suicidality using random-effects meta-analysis and provided a narrative 25 
summary of estimates of PTSD and self-harm. 26 
Findings: We found 23 studies that reported on these mental health indicators among PWID. The 27 
pooled estimate for current severe depressive symptomology was 42.0% (95% confidence interval 28 
[CI] = 21.3, 62.8%), and for a depression diagnosis was 28.7% (95% CI = 20.8, 36.6%). With much 29 
variation, the pooled lifetime prevalence of a suicide attempt was 22.1% (95% CI = 19.3, 24.9%). 30 
There were only two studies each that reported on PTSD and non-suicidal self-harm among PWID. 31 
Interpretation: Recent data investigating these mental health indicators among PWID was limited, 32 
particularly from low- and middle-income countries. Even so, estimates were high and call for further 33 
research into the epidemiology of such mental health disorders and self-harming behaviours, as well 34 
as the promotion of integrated mental health and substance dependence treatment. Finally, 35 
incorporating suicide prevention strategies into services accessed by PWID must be considered as a 36 
harm reduction priority.  37 
Keywords: Mental health, depression, suicide, people who inject drugs, injecting drug use, PTSD, 38 
self-harm. 39 




1. Introduction 41 
Mental disorders, including depression and self-harm, are a major source of morbidity and mortality 42 
worldwide (Vigo et al., 2016; WHO, 2013, 2017). It is common for people who inject drugs (PWID) 43 
to be exposed to distressing circumstances, such as unstable housing, unemployment, legal problems, 44 
physical injury or disease (Degenhardt et al., 2017; Havens et al., 2006; Larney et al., 2017; Milloy et 45 
al., 2008; Richardson et al., 2014; Richardson et al., 2010), as well as having experienced traumatic 46 
events such as childhood maltreatment and stigma (Darke and Torok, 2013; Wilson et al., 2014). Such 47 
events, particularly in combination, may increase the risk of mental disorders among this population.  48 
Although injecting drug use is not necessarily indicative of substance use disorders, their comorbidity 49 
with mental health problems can elevate the risk of poor mental, physical and behavioural outcomes 50 
in PWID (Bartoli et al., 2014; Darke and Torok, 2013; Lemstra et al., 2011; Mills et al., 2006; 51 
Plotzker et al., 2007; Teesson et al., 2015). For example, depression is consistently associated with a 52 
higher prevalence of overdose, injecting-related injuries and diseases, and sharing injecting equipment 53 
among PWID (Lemstra et al., 2011; Teesson et al., 2015). Considering this, better evidence is needed 54 
to inform integrated treatment services and address the mental health needs of PWID. 55 
There has been no systematic review of the evidence of mental health indicators among PWID. This 56 
paper aimed to synthesise the existing literature on the prevalence of mental health problems among 57 
PWID, specifically: depression, post-traumatic stress disorder (PTSD), suicidal thoughts, plans and 58 
attempts, and non-suicidal self-harm. 59 




2. Methods 61 
This systematic review uses data gathered for a previous review (PROSPERO registration numbers 62 
CRD42016052858 and CRD42016052853) investigating sociodemographic and risk characteristics of 63 
PWID. Details of the methodology have been described elsewhere (Degenhardt et al., 2017). 64 
Adhering PRISMA and GATHER guidelines (Appendix 1-22) we searched peer-reviewed (Medline, 65 
Embase, and PsycINFO) and grey literature, and online databases for data published from January 66 
2008-June 2018 (see Appendix 3-42). We then circulated data requests to international experts and 67 
agencies. 68 
Two researchers provided independent screening, and conflicts were resolved by a third reviewer. We 69 
included all studies providing sociodemographic or risk characteristics, or reporting on blood borne 70 
viruses, overdose, mental health, or injecting related injuries and diseases among PWID, and did not 71 
limit the search results by language. Studies were excluded if they: 72 
a) had fewer than 40 participants; 73 
b) limited participants on key outcomes except for treatment status (e.g. gender, age, HIV status, 74 
prison status etc.); or 75 
c) were a follow-up study of a previously recruited sample (e.g. cohort studies). 76 
Suicide, self-harm, depression and PTSD data were included in this review. Where two studies 77 
provided data on the same sample, the study with the most complete reporting on the variables of 78 
interest was retained. Study quality was assessed using previously developed grading systems of 79 
methodology and literature type (Mathers et al., 2008) (see Appendix 52).   80 
The studies that met inclusion criteria for this paper were those that reported on experience of suicide 81 
attempt, suicide plan, suicidal thoughts, and non-suicidal self-harm (past month/current, 6 months, 12 82 
months and lifetime). Self-report measures were used as there were no studies that reported using a 83 
validated scale. Also, studies that assessed current depression, or depressive symptomology, and 84 
 





PTSD using validated screening scales or diagnostic interviews (i.e. any peer-reviewed 85 
scales/inventories with publications supporting their validity and reliability) were included. We did 86 
not limit the validated screening scales in the extraction phase, although studies that reported self-87 
report depression or PTSD (i.e. answering yes to “have you been diagnosed with depression/PTSD”) 88 
were excluded due to low validity. Although definitions of current or active PWID differ between 89 
studies, we define PWID as those who have injected drugs within the previous 12 months for this 90 
review. 91 
To generate a pooled estimate of the prevalence of depression, and the proportion who had attempted 92 
suicide, we ran a random-effects meta-analysis in STATA 15 using the ‘metan’ command. For studies 93 
that reported depressive symptomology by severity, we categorised estimates to reflect mild to severe, 94 
moderate to severe, and severe symptomology. Estimates from studies that used measures to diagnose 95 
participants with major depressive disorder (MDD) were pooled separately. Studies providing 96 
estimates of suicide attempts among PWID were pooled by timeframe (12 months and lifetime).  97 




3. Results 99 
Of 61,077 studies and reports, screened for eligibility for the original review, information on 100 
characteristics and harms among PWID was extracted from 1,381 sources. Among those, there were 101 
22 eligible studies of depression, PTSD, suicidality or non-suicidal self-harm (see flowchart in 102 
Appendix 63). Nearly all (n=20) included studies were peer-reviewed journal articles (Table 1). There 103 
were 39 estimates, and most were from samples recruited in one city (n=20), while six were recruited 104 
from multiple geographical sites across a country.  105 
3.1. Depression 106 
From 12 studies, there were five different inventories used to measure depression or depressive 107 
symptomology: the Center for Epidemiologic Studies Depression Scale (CES-D; n=4), the Patient 108 
Health Questionnaire (PHQ-9; n=3), the Mini International Neuropsychiatric Interview (MINI; n=2), 109 
the John Hopkins symptoms checklist for anxiety and depression (n=2), and the Depression Anxiety 110 
Stress Scale 21 (DASS-21; n=1). 111 
Among PWID, 28.7% (95% confidence intervals [CI] = 20.8, 36.6%; I2 = 91.5%) met diagnostic 112 
criteria for MDD (Figure 1). Four estimates representing PWID sampled from Tanzania, the United 113 
States, and Australia were pooled to generate this estimate (see study details in Table 1). An estimated 114 
42.0% (95%CI = 21.3, 62.8%; I2 = 99.1%) of PWID screened as having ‘severe’ depressive 115 
symptomology. Estimates ranged from 17.3% (95%CI = 13.9, 21.2%) (Armstrong et al., 2013b) to 116 
75.1% (95%CI = 69.3, 80.3%) (Li et al., 2015) from five different studies in India, the United States, 117 
New Zealand, Canada and China. 118 
The prevalence of moderate to severe depressive symptomology among PWID was estimated to be 119 
59.7% (95%CI = 42.7, 76.8%; I2 = 99.6%), derived from seven estimates from six countries. Finally, 120 
the pooled mild to severe depression estimate was 78.0% (95%CI = 66.1, 89.8%; I2 = 97.4%), which 121 
included samples of PWID from the United States, New Zealand, Canada and China. Although the 122 
range in the estimates was notably smaller when pooling mild to severe depression, with the lowest 123 
 





and highest point estimates being 25.3 percentage points apart (I2=97.4%), there was less 124 
heterogeneity when pooling the MDD estimates (I2=91.5%).  125 
3.2. Suicidality 126 
There were 11 studies that included data on self-reported suicide attempts among PWID across four 127 
different time frames, comprising past month (n=1), past 6 months (n=2), past 12 months (n=5) and 128 
lifetime (n=4) (Figure 1). Estimates of past year attempted suicide among PWID ranging from 3.0% 129 
(95%CI = 1.4, 5.6%) from an Australian sample (Darke and Torok, 2013) to 36.2% (95%CI = 31.8, 130 
40.9%) among an Indian sample (Armstrong et al., 2013b). Estimates of lifetime suicide attempts 131 
were less heterogenous (I2=34.2%), resulting in a pooled estimate of 22.1% (95%CI = 19.3, 24.9%) 132 
and a range of 20.0% (95%CI = 17.6, 22.6%; (Backmund et al., 2011)) to 25.7% (95%CI = 20.8, 133 
31.0%; (Darke and Torok, 2013)).  134 
Only five studies reported on suicidal thoughts (n=5) or planning (n=2) (Appendix 74). Estimates of 135 
suicidal thoughts were high, with three studies reporting estimates of over 40% within the previous 136 
year (Slovenia, past 12 months: 41.0% (Reitox National Focal Point, 2010); Puerto Rico, past 6 137 
months: 43.8% (Zerden et al., 2010); and India, past 12 months 53.1% (Armstrong et al., 2013b)). 138 
3.3. Non-suicidal self-harm 139 
Due to the small numbers of studies we were unable to pool the PTSD or non-suicidal self-harm data. 140 
There were two Australian studies that investigated non-suicidal self-harm among PWID. Among 141 
those recruited from a supervised injecting facility in Sydney, Australia, the most recent estimate of 142 
lifetime engagement in non-suicidal self-harm was 13.0% (KPMG, 2010). In the second study, Darke 143 
and Torok (2013) found nearly one in four PWID recruited from needle syringe programs in Sydney, 144 
Australia had ever engaged in non-suicidal self-harm (23.7%) and nearly one in ten had done so in the 145 
previous year (8.0%). 146 
 





3.4. PTSD 147 
Two studies that met inclusion criteria reported clinically assessed PTSD among PWID. Using the 148 
MINI inventory, a study in the United States reported a prevalence of 14.8% (Havens et al., 2013). 149 
The second study from an Australian sample found that 42.0% scored >3 on the Primary Care PTSD 150 
(PC-PTSD) screening tool, indicating “possible presence” of PTSD (Larance et al., 2015). 151 
 152 




4. Discussion 154 
4.1 Main findings 155 
To our knowledge, this is the first systematic review synthesising the recent evidence of depression, 156 
PTSD, suicidality and non-suicidal self-harm among PWID. We estimated that over half of PWID had 157 
moderate to severe depressive symptomology, and one in six had attempted suicide in the previous 158 
year. Our results call for further investigation to expand our global understanding of the prevalence of 159 
mental health disorders and self-harming behaviours among PWID. 160 
4.2. Implications 161 
Studies among the general population have found that less than 1% had attempted suicide in the 162 
previous year and less than 3% had ever attempted suicide (Borges et al., 2010; Bromet et al., 2017). 163 
Our review found that estimates of recent attempts were as high as one third in samples of PWID 164 
from Taiwan and India (Armstrong et al., 2013b; Lee et al., 2011). Considering previous suicide 165 
attempts are associated with future fatal and non-fatal attempts (Borges et al., 2000), as well as 166 
morbidity relating to the method used (Dunn and Lopez, Updated 2019 Jul 3; Warner-Smith et al., 167 
2002), there is substantial opportunity for intervention within this group. The scale up of suicide 168 
prevention strategies targeting PWID must be considered in order to reduce the risk of suicide 169 
fatalities. 170 
Around 5% and 0.3% of the population are estimated to have current MDD and PTSD, respectively 171 
(Baxter et al., 2014a; Baxter et al., 2014b). We found that among PWID these estimates are many 172 
magnitudes higher. There is ample evidence that mental health and substance use comorbidities 173 
contribute to poorer prognosis on health outcomes and extensive morbidity and mortality (Allsop, 174 
2008). Integrating mental health and substance dependence treatment with a multifaceted approach 175 
has been widely considered best practice (Roberts et al., 2015; Torrens et al., 2012). Although there 176 
are several models that have been developed, a review found that including a harm reduction 177 
approach (e.g. discouraging abstinence only conditions and providing access to sterile needles and 178 
syringes) was an important element to be considered in integrated mental health and substance 179 




4.3. Limitations 181 
We noted several limitations. Firstly, there were few studies, particularly for non-suicidal self-harm 182 
and PTSD, that met our inclusion criteria. We know that data on mental health indicators has been 183 
researched extensively in conjunction with substance use disorders; however, compared to people 184 
with substance dependence that do not inject, PWID have been found to have an elevated risk of 185 
depression and suicidality (Cepeda et al., 2012; Darke and Kaye, 2004). Depression, PTSD and 186 
suicidality are also associated with engaging in injecting risk behaviours, increasing the likelihood of 187 
contracting blood borne viruses (Armstrong et al., 2013a; Mackesy-Amiti et al., 2014; Plotzker et al., 188 
2007). Future research monitoring the prevalence of psychiatric comorbidities among PWID is 189 
important for informing harm reduction and treatment strategies that respond to major mental and 190 
physical health issues. 191 
Much of the available data was from high-income countries. The lack of data investigating self-192 
harming behaviours among people who use drugs in low- and middle-income countries, where 75% of 193 
suicides occur (World Health Organization (WHO), 2014), has been highlighted in a recent review 194 
(Breet et al., 2018). Updated epidemiological research investigating these harms, globally, remain 195 
important for measuring our progress in improving outreach of intervention strategies and reducing 196 
self-harming behaviour. 197 
Several screening scales and inventories were used to measure depression, and cut-off scores of 198 
severities were not always consistent. Therefore, variability in our results might be explained by the 199 
differences in these inventories or the cut-off scores used. We found that most inventories were 200 
measuring current depressive symptomology, compared to diagnosing MDD. There were too few 201 
studies to undertake meta-regressions exploring associations between inventories and depression 202 
prevalence; however, we found that among the few MDD estimates there was less heterogeneity than 203 
the scales measuring severe depressive symptomology.  204 
Finally, there is a lack of data that is representative of diverse geographical regions. Notably, two 205 
studies set in India using the same scale to measure (moderate to severe) depression found a 51-206 




estimate sampled male PWID from one city (Delhi), while the lower estimate was a sample of both 208 
men and women recruited from 15 cities. The latter is an example of incorporating mental health 209 
screening in large-scale, routine surveillance data collection and could be employed by more national-210 
level research to better inform our global understanding of mental health in PWID (WHO, 2016). 211 
4.4. Conclusion 212 
We estimate that perhaps one in three PWID has been diagnosed with depression and one in four had 213 
ever attempted suicide. There were few studies identified and were primarily from high-income 214 
countries. Results call for further research examining the prevalence of mental health indicators 215 
among PWID and for the availability of integrated mental health and substance dependence treatment 216 






Table 1: Study-level information for estimates of depression, post-traumatic stress disorder (PTSD), suicide attempts, and non-suicidal 














Depression           
Australia Sub-national 2014 A1 A Recruited people who 
tampered with pharmaceutical 
opioids 
PHQ-9 606 Moderate to severe (score ≥10) 61.0 (Larance et al., 
2015) 
Australia City 2004 A1 A People who inject drugs 
(PWID) recruited from needle-
syringe programs (NSPs) and a 
primary health center 
MINI 103 Mood disorder diagnosis 49.5 (Gibbie et al., 
2011) 
Canada City 2010 A2 B1 Set in Saskatoon, a region with 
a high prevalence of 
indigenous/First Nations 
people. Nearly 90% of the 
sample were Aboriginal (First 
Nations, Metis or Inuit) 
CES-D 603 Mild to severe (score ≥16) 
Severe (score ≥23) 
81.4 
57.7 
(Lemstra et al., 
2011) 
China City 2013 A1 B1 People who primarily inject 
heroin recruited from three 
different NSPs 
CES-D 257 Mild to severe (score ≥16) 
 
93.4 (Li et al., 2015) 
Moderate to severe (score ≥21) 
 
86.4 
Severe (score ≥25) 75.1 
India National 2013 A1 B1 PWID recruited from 15 cities 
around India 











Men who inject drugs who are 






Moderate to severe (score ≥15) 84.4 (Armstrong et al., 
2013b) 
 Severe (score ≥20) 17.4 
New Zealand National 2015 A1 A PWID recruited from NSPs 
and pharmacies 
DASS-21 225 Mild to severe (score ≥10) 68.4 (Hay et al., 2017) 
Moderate to severe (score ≥NR*) 54.2 
Severe (score ≥NR) 32.0 
Tanzania City 2012 A1 C People who were enrolled in a 
methadone program recruited 




for Depression -25 
400 Depression diagnosis 22.0 (Lambdin et al., 
2013) 
Tanzania City 2013 A1 C People who were enrolled in a 
methadone program recruited 
John Hopkins 
Symptoms Checklist 
for Depression -25 


















from Muhimbili National 
Hospital 
Ukraine Sub-national 2015 A1 A People who were diagnosed 
with ICD-10 opioid use 
disorder 
CES-D 1613 Moderate to severe (score ≥10) 53.2 (Marcus et al., 
2017) 
United States Sub-national 2012 A1 A PWID recruited through 
respondent driven sampling 
(RDS) 
CES-D 454 Mild to severe (score ≥NR) 68.1 (Grau et al., 2016) 
Moderate to severe (score ≥NR) 45.4 
Severe (score ≥NR) 28.2 
United States Sub-national 2010 A1 B1 PWID recruited from 
Appalachian, Kentucky 
MINI version 5.0 392 Severe:  
Major depressive disorder 
diagnosis 
28.1 (Havens et al., 
2013) 
PTSD           
Australia Sub-national 2014 A1 A People who tampered with 
pharmaceutical opioids 
PC-PTSD 606 Possible presence of PTSD: 
Score >3 
42.0 (Larance et al., 
2015) 
United States Sub-national 2010 A1 B1 PWID recruited from 
Appalachian, Kentucky 
MINI version 5.0 392 DSM-IV PTSD diagnosis 14.8 (Havens et al., 
2013) 
Suicide      Timeframe  Definition   
Taiwan Sub-national 2008 A1 B1 People who had recently used 
heroin and were on methadone 
maintenance therapy, recruited 
from four different clinics 
Month 523 Attempted suicide 32.7 (Lee et al., 2011) 
Canada City 2011 A1 B1 Street-recruited PWID 6 months 1240 Attempted suicide 5.7 (Artenie et al., 
2015) 
India Sub-national 2006 A1 C Male PWID who were mostly 
unstably housed (89.0%) 
6 months 449 Attempted to take your own life 4.2 (Sarin et al., 2013) 
Australia City 2012 A1 B1 PWID recruited through NSPs 
who were injecting weekly or 
more frequently 
12 months 300 Deliberate self-harm with the 
intention of causing death 
3.0 (Darke and Torok, 
2013) Lifetime 25.7 
Canada City 2013 A1 B1 PWID recruited using RDS 12 months 272 Attempted suicide 7.7 (Shaw et al., 2015) 
India City 2012 A1 B1 Men who inject drugs who are 
not enrolled in treatment 
12 months 450 Attempted suicide 36.3 (Armstrong et al., 
2013b) 
Puerto Rico National 2007 A1 B1 PWID recruited using RDS 12 months 124 Attempted suicide 27.4 (Zerden et al., 
2010) 
Slovenia National 2008 B2 B1 Data collected from PWID 
through 10 low-threshold 
programs 
12 months 107 Tried to commit suicide 11.2 (Reitox National 
Focal Point, 2010) 
Germany City 1997 A1 C PWID requiring heroin 
detoxification recruited from a 
tertiary hospital 
Lifetime 1049 Deliberate self-harm 
with the intention of causing 
death 
20.0 (Backmund et al., 
2011) 
Nepal Sub-national 2013 A1 A PWID recruited from treatment 
settings 

















Sweden City 2009 A1 C PWID recruited using RDS Lifetime 68 Suicide attempt 22.1 (Hakansson et al., 
2012) 
Self-harm           
Australia City 2012 A1 B1 PWID recruited through NSPs 
who were injecting weekly or 
more frequently 
12 months 300 Non-suicidal self-harm was 
defined as the deliberate 
destruction of body tissue without 
conscious suicidal intent 
8.0 (Darke and Torok, 
2013) Lifetime 23.7 
Australia City 2010 B3 C New entrants to the Medically 
Supervised Injecting Centre in 
Kings Cross, Sydney 
Lifetime 687 Deliberate self-harm 12.9 (KPMG, 2010) 
2009 813 13.9 
2008 784 9.8 
Note: CES-D: Center for Epidemiologic Studies Depression Scale; DASS-21: Depression Anxiety Stress Scale 21; DSM: Diagnostic and Statistical Manual of Mental Disorders; ICD-10: 10th 
revision of the International Statistical Classification of Diseases and Related Health Problems; MINI: Mini International Neuropsychiatric Interview; NR: Not reported; NSP: Needle-syringe 
exchange programs; PHQ-9: Patient Health Questionnaire; PC-PTSD: Primary Care PTSD screen; RDS: Respondent-driven sampling. 
Literature and method grading systems are in Appendix 35. 
 
 










Figure 1. Prevalence of depression and depressive symptomology, and estimates of suicide attempts 





Allsop, S., 2008. Drug use and mental health: effective responses to co-occuring drug and mental 
health problems, 1st ed ed. IP Communications, East Hawthorn, Vic. 
Armstrong, G., Jorm, A.F., Samson, L., Joubert, L., Nuken, A., Singh, S., Kermode, M., 2013a. 
Association of Depression, Anxiety, and Suicidal Ideation With High-Risk Behaviors Among 
Men Who Inject Drugs in Delhi, India.  64(5), 502-510. 10.1097/QAI.0b013e3182a7ef21. 
Armstrong, G., Nuken, A., Samson, L., Singh, S., Jorm, A.F., Kermode, M., 2013b. Quality of life, 
depression, anxiety and suicidal ideation among men who inject drugs in Delhi, India. BMC 
Psychiatry 13(151), 11. http://www.biomedcentral.com/1471-244X/13/151. 
Artenie, A.A., Bruneau, J., Zang, G., Lesperance, F., Renaud, J., Tremblay, J., Jutras-Aswad, D., 
2015. Associations of substance use patterns with attempted suicide among persons who 
inject drugs: Can distinct use patterns play a role? Drug and Alcohol Dependence 147, 208-
214.  
Backmund, M., Meyer, K., Schutz, C., Reimer, J., 2011. Factors associated with suicide attempts 
among injection drug users. Substance Use & Misuse 46(12), 1553-1559. 
http://dx.doi.org/10.3109/10826084.2011.564443. 
Bartoli, F., Carra, G., Brambilla, G., Carretta, D., Crocamo, C., Neufeind, J., Baldacchino, A., 
Humphris, G., Clerici, M., 2014. Association between depression and non-fatal overdoses 
among drug users: a systematic review and meta-analysis. Drug Alcohol Depend 134, 12-21. 
10.1016/j.drugalcdep.2013.10.007. 
Baxter, A.J., Scott, K.M., Ferrari, A.J., Norman, R.E., Vos, T., Whiteford, H.A., 2014a. Challenging 
the myth of an "epidemic" of common mental disorders: Trends in the global prevalence of 





Baxter, A.J., Vos, T., Scott, K.M., Ferrari, A.J., Whiteford, H.A., 2014b. The global burden of 
anxiety disorders in 2010. Psychological Medicine 44(11), 2363-2374. 
10.1017/S0033291713003243. 
Borges, G., Nock, M.K., Haro Abad, J.M., Hwang, I., Sampson, N.A., Alonso, J., Andrade, L.H., 
Angermeyer, M.C., Beautrais, A., Bromet, E., Bruffaerts, R., de Girolamo, G., Florescu, S., 
Gureje, O., Hu, C., Karam, E.G., Kovess-Masfety, V., Lee, S., Levinson, D., Medina-Mora, 
M.E., Ormel, J., Posada-Villa, J., Sagar, R., Tomov, T., Uda, H., et al., 2010. Twelve-month 
prevalence of and risk factors for suicide attempts in the World Health Organization World 
Mental Health Surveys. J Clin Psychiatry 71(12), 1617-1628. 10.4088/JCP.08m04967blu. 
Borges, G., Walters, E.E., Kessler, R.C., 2000. Associations of Substance Use, Abuse, and 
Dependence with Subsequent Suicidal Behavior. American Journal of Epidemiology 151(8), 
781-789. 10.1093/oxfordjournals.aje.a010278. 
Breet, E., Goldstone, D., Bantjes, J., 2018. Substance use and suicidal ideation and behaviour in low- 
and middle-income countries: a systematic review. BMC public health 18(1), 549-549. 
10.1186/s12889-018-5425-6. 
Bromet, E.J., Nock, M.K., Saha, S., Lim, C.C.W., Aguilar-Gaxiola, S., Al-Hamzawi, A., Alonso, J., 
Borges, G., Bruffaerts, R., Degenhardt, L., de Girolamo, G., de Jonge, P., Florescu, S., 
Gureje, O., Haro, J.M., He, Y., Hu, C., Karam, E.G., Kovess-Masfety, V., Lee, S., Lepine, J., 
Mneimneh, Z., Navarro-Mateu, F., Ojagbemi, A., Posada-Villa, J., et al., 2017. Association 
Between Psychotic Experiences and Subsequent Suicidal Thoughts and Behaviors: A Cross-
National Analysis From the World Health Organization World Mental Health Surveys. 





Cepeda, A., Kaplan, C., Neaigus, A., Cano, M.A., Villarreal, Y., Valdez, A., 2012. Injecting 
transition risk and depression among Mexican American non-injecting heroin users. Drug 
Alcohol Depend 125 Suppl 1, S12-17. 10.1016/j.drugalcdep.2012.05.035. 
Darke, S., Kaye, S., 2004. Attempted suicide among injecting and noninjecting cocaine users in 
Sydney, Australia. J Urban Health 81(3), 505-515. 10.1093/jurban/jth134. 
Darke, S., Torok, M., 2013. Childhood physical abuse, non-suicidal self-harm and attempted suicide 
amongst regular injecting drug users. Drug Alcohol Depend 133(2), 420-426. 
10.1016/j.drugalcdep.2013.06.026. 
Degenhardt, L., Peacock, A., Colledge, S., Leung, J., Grebely, J., Vickerman, P., Stone, J., 
Cunningham, E.B., Trickey, A., Dumchev, K., Lynskey, M., Griffiths, P., Mattick, R.P., 
Hickman, M., Larney, S., 2017. Global prevalence of injecting drug use and 
sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who 
inject drugs: a multistage systematic review. The Lancet Global Health 5(12), e1192-e1207. 
10.1016/s2214-109x(17)30375-3. 
Dunn, R.J., Lopez, R.A., Updated 2019 Jul 3. Strangulation Injuries, StatPearls. StatPearls 
Publishing, Treasure Island (FL). 
Gibbie, T.M., Hides, L.M., Cotton, S.M., Lubman, D.I., Aitken, C., Hellard, M., 2011. The 
relationship between personality disorders and mental health, substance use severity and 
quality of life among injecting drug users. Medical Journal of Australia 195(3 SUPPL.), S16-
S21.  
Grau, L.E., Zhan, W., Heimer, R., 2016. Prevention knowledge, risk behaviours and seroprevalence 





Hakansson, A., Isendahl, P., Wallin, C., Berglund, M., 2012. Respondent-driven sampling in a 
syringe exchange setting. Scandinavian Journal of Public Health 40(8), 725-729. 
http://dx.doi.org/10.1177/1403494812465028. 
Havens, J.R., Lofwall, M.R., Frost, S.D.W., Oser, C.B., Leukefeld, C.G., Crosby, R.A., 2013. 
Individual and network factors associated with prevalent hepatitis C infection among rural 
Appalachian injection drug users. American Journal of Public Health 103(1), e44-52. 
http://dx.doi.org/10.2105/AJPH.2012.300874. 
Havens, J.R., Sherman, S.G., Sapun, M., Strathdee, S.A., 2006. Prevalence and correlates of suicidal 
ideation among young injection vs. noninjection drug users. Subst Use Misuse 41(2), 245-
254. 10.1080/10826080500391811. 
Hay, B., Henderson, C., Maltby, J., Canales, J.J., 2017. Influence of peer-based needle exchange 
programs on mental health status in people who inject drugs: A nationwide New Zealand 
study. Frontiers in Psychiatry 7 (JAN) (no pagination)(211). 
http://dx.doi.org/10.3389/fpsyt.2016.00211. 
KPMG, 2010. Further evaluation of the Medically Supervised Injecting Centre during its extended 
Trial period (2007-2011).  
Lambdin, B.H., Bruce, R.D., Chang, O., Nyandindi, C., Sabuni, N., Zamudio-Haas, S., McCurdy, S., 
Masao, F., Ivo, Y., Msami, A., Ubuguy, O., Mbwambo, J., 2013. Identifying Programmatic 
Gaps: Inequities in Harm Reduction Service Utilization among Male and Female Drug Users 
in Dar es Salaam, Tanzania. PLoS ONE 8 (6) (no pagination)(e67062). 
http://dx.doi.org/10.1371/journal.pone.0067062. 
Lambdin, B.H., Masao, F., Chang, O., Kaduri, P., Mbwambo, J., Magimba, A., Sabuni, N., Bruce, 
R.D., 2014. Methadone treatment for HIV prevention- Feasibility, retention, and predictors of 
attrition in Dar es Salaam, Tanzania: A Retrospective cohort study. Clinical Infectious 




Larance, B., Lintzeris, N., Bruno, R., Peacock, A., Cama, E., Ali, R., Kihas, I., Hordern, A., White, 
N., Degenhardt, L., 2015. The characteristics of a cohort who tamper with prescribed and 
diverted opioid medications. Journal of Substance Abuse Treatment 58. 
http://dx.doi.org/10.1016/j.jsat.2015.06.001. 
Larney, S., Peacock, A., Mathers, B.M., Hickman, M., Degenhardt, L., 2017. A systematic review of 
injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend 
171, 39-49. 10.1016/j.drugalcdep.2016.11.029. 
Lee, T.S.H., Shen, H.C., Wu, W.H., Huang, C.W., Yen, M.Y., Wang, B.E., Chuang, P., Shih, C.Y., 
Chou, Y.C., Liu, Y.L., 2011. Clinical characteristics and risk behavior as a function of HIV 
status among heroin users enrolled in methadone treatment in northern Taiwan. Substance 
Abuse Treatment, Prevention, & Policy 6, 6. http://dx.doi.org/10.1186/1747-597X-6-6. 
Lemstra, M., Rogers, M., Thompson, A., Moraros, J., Buckingham, R., 2011. Risk indicators of 
depressive symptomatology among injection drug users and increased HIV risk behaviour. 
The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie 56(6), 358-366.  
Li, J., Gu, J., Lau, J.T., Chen, H., Mo, P.K., Tang, M., 2015. Prevalence of depressive symptoms and 
associated factors among people who inject drugs in China. Drug and Alcohol Dependence 
151, 228-235.  
Mackesy-Amiti, M.E., Donenberg, G.R., Ouellet, L.J., 2014. Psychiatric correlates of injection risk 
behavior among young people who inject drugs. Psychology of Addictive Behaviors 28(4), 
1089-1095. 10.1037/a0036390. 
Marcus, R., Makarenko, I., Mazhnaya, A., Zelenev, A., Polonsky, M., Madden, L., Filippovych, S., 
Dvoriak, S., Springer, S.A., Altice, F.L., 2017. Patient preferences and extended-release 
naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug and Alcohol 




Mathers, B.M., Degenhardt, L., Phillips, B., Wiessing, L., Hickman, M., Strathdee, S.A., Wodak, A., 
Panda, S., Tyndall, M., Toufik, A., Mattick, R.P., 2008. Global epidemiology of injecting 
drug use and HIV among people who inject drugs: a systematic review. The Lancet 
372(9651), 1733-1745. https://doi.org/10.1016/S0140-6736(08)61311-2. 
Milloy, M.J., Wood, E., Small, W., Tyndall, M., Lai, C., Montaner, J., Kerr, T., 2008. Incarceration 
experiences in a cohort of active injection drug users. Drug and Alcohol Review 27(6), 693-
699. 10.1080/09595230801956157. 
Mills, K.L., Teesson, M., Ross, J., Peters, L., 2006. Trauma, PTSD, and Substance Use Disorders: 
Findings From the Australian National Survey of Mental Health and Well-Being.  163(4), 
652-658. 10.1176/ajp.2006.163.4.652. 
Mueser, K.T., Gingerich, S., 2013. Treatment of Co-Occurring Psychotic and Substance Use 
Disorders. Social Work in Public Health 28(3-4), 424-439. 10.1080/19371918.2013.774676. 
Ojha, S.P., Sigdel, S., Verthien, U., Khadga, P.K., 2014. HIV epidemiology in Nepal-"South Asian 
cocktail" a drug use pattern in Nepal and its correlation with spread of HIV. Indian Journal of 
Psychiatry 55, S46-S47. http://dx.doi.org/10.1186/1477-7517-11-17;. 
Plotzker, R.E., Metzger, D.S., Holmes, W.C., 2007. Childhood Sexual and Physical Abuse Histories, 
PTSD, Depression, and HIV Risk Outcomes in Women Injection Drug Users: A Potential 
Mediating Pathway. The American Journal on Addictions 16(6), 431-438. 
10.1080/10550490701643161. 
Reitox National Focal Point, 2010. 2009 National Report (2008 data) to the EMCDDA. Slovenia: 
New Development, Trends and in-depth information on selected issues. National Institute of 
Public Health. 
Richardson, L., DeBeck, K., Feng, C., Kerr, T., Wood, E., 2014. Employment and risk of injection 





Richardson, L., Wood, E., Li, K., Kerr, T., 2010. Factors associated with employment among a 
cohort of injection drug users.  29(3), 293-300. 10.1111/j.1465-3362.2009.00141.x. 
Roberts, N.P., Roberts, P.A., Jones, N., Bisson, J.I., 2015. Psychological interventions for post-
traumatic stress disorder and comorbid substance use disorder: A systematic review and 
meta-analysis. Clinical Psychology Review 38, 25-38. 
https://doi.org/10.1016/j.cpr.2015.02.007. 
Sabri, B., McFall, A.M., Solomon, S.S., Srikrishnan, A.K., Vasudevan, C.K., Anand, S., Celentano, 
D.D., Mehta, S.H., Kumar, S., Lucas, G.M., 2017. Gender differences in factors related to 
HIV risk behaviors among people who inject drugs in north-east India. PLoS ONE 12(1).  
Sarin, E., Singh, B., Samson, L., Sweat, M., 2013. Suicidal ideation and HIV risk behaviors among a 
cohort of injecting drug users in New Delhi, India. Substance Abuse Treatment, Prevention, 
and Policy 8, 2.  
Shaw, A., Lazarus, L., Pantalone, T., LeBlanc, S., Lin, D., Stanley, D., Chepesiuk, C., Patel, S., 
Tyndall, M., 2015. Risk environments facing potential users of a supervised injection site in 
Ottawa, Canada. Harm Reduction Journal 12, 49.  
Teesson, M., Marel, C., Darke, S., Ross, J., Slade, T., Burns, L., Lynskey, M., Memedovic, S., 
White, J., Mills, K.L., 2015. Long-term mortality, remission, criminality and psychiatric 
comorbidity of heroin dependence: 11-year findings from the Australian Treatment Outcome 
Study. Addiction 110(6), 986-993. 10.1111/add.12860. 
Torrens, M., Rossi, P.C., Martinez-Riera, R., Martinez-Sanvisens, D., Bulbena, A., 2012. Psychiatric 
Co-Morbidity and Substance Use Disorders: Treatment in Parallel Systems or in One 
Integrated System? Substance Use & Misuse 47(8-9), 1005-1014. 
10.3109/10826084.2012.663296. 
Vigo, D., Thornicroft, G., Atun, R., 2016. Estimating the true global burden of mental illness. Lancet 




Warner-Smith, M., Darke, S., Day, C.A., 2002. Morbidity associated with non-fatal heroin overdose. 
Addiction 97, 963-967.  
Wilson, H., Brener, L., Mao, L., Treloar, C., 2014. Perceived discrimination and injecting risk 
among people who inject drugs attending Needle and Syringe Programmes in Sydney, 
Australia. Drug and Alcohol Dependence 144, 274-278. 
https://doi.org/10.1016/j.drugalcdep.2014.08.018. 
World Health Organization (WHO), 2013. Comprehensive mental health action plan 2013-2020. 
World Health Organization. 
World Health Organization (WHO), 2014. Preventing suicide: a global imperative. Geneva, 
Switzerland. 
World Health Organization (WHO), 2016. Practice manual for establishing and maintaining 
surveillance systems for suicide attempts and self-harm. Geneva, Switzerland, p. 79. 
World Health Organization (WHO), 2017. Depression and Other Common Mental Disorders: Global 
Health Estimates. Geneva. 
Zerden, L.D.S., Marilis Lopez, L., Lundgren, L.M., 2010. Needle sharing among Puerto Rican 
injection drug users in Puerto Rico and Massachusetts: place of birth and residence matter. 
Substance Use & Misuse 45(10), 1605-1622. http://dx.doi.org/10.3109/10826081003682842. 
 
 
